Cross-Linked Lipoic Acid Trisulfide Nanoparticles: Revisiting H 2 S Intervention as a Stand-alone Modality for Cancer Therapy
Source abstract
Abstract
Despite the pleiotropic anticancer potential of the endogenous gasotransmitter hydrogen sulfide (H 2 S), achieving sustained and adequate intratumoral H 2 S supply remains a persistent challenge, hindering its advancement as a stand-alone therapeutic modality. Herein, we introduce cross-linked lipoic acid trisulfide nanoparticles (cLATN) that integrate both the H 2 S donor and transporter within a single precursor, wherein each unit theoretically yields one molecule of H 2 S, enabling stoichiometric H 2 S loading. cLATN effectively enter tumor cells via thiol-mediated uptake and are depolymerized by glutathione to trigger sufficient H 2 S release in tumor tissues for more than 48 h, far surpassing current H 2 S-based anticancer agents, which generally persist for only a few hours. Therapeutically, cLATN achieve an impressive tumor inhibition rate of 83% with favorable biocompatibility, far exceeding the clinical agent doxorubicin in both efficacy and safety. This work affirms its potential for cancer treatment, renewing interest in positioning H 2 S intervention as a stand-alone modality toward broader clinics.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Sulfur Compounds in Biology · Metalloenzymes and iron-sulfur proteins · Enzyme function and inhibition
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Biomedical Engineering and National Engineering Research Center for Biomaterials
Sichuan University
Funding
National Natural Science Foundation of China
References (41)
Show source-provided references
1. 10.1038/s41420-024-01868-w10.1038/s41420-024-01868-w ↗
2. 10.1038/s41392-025-02231-w10.1038/s41392-025-02231-w ↗
3. 10.1038/nrd242510.1038/nrd2425 ↗
4. 10.1096/fj.02-0211hyp10.1096/fj.02-0211hyp ↗
5. 10.1111/bph.1277310.1111/bph.12773 ↗
6. 10.1021/jacs.2c0766910.1021/jacs.2c07669 ↗
7. 10.3390/molecules2711338910.3390/molecules27113389 ↗
8. 10.1016/j.redox.2020.10156410.1016/j.redox.2020.101564 ↗
9. 10.1371/journal.pone.012378110.1371/journal.pone.0123781 ↗
10. 10.1146/annurev-pharmtox-010510-10050510.1146/annurev-pharmtox-010510-100505 ↗
11. 10.1111/bph.1236810.1111/bph.12368 ↗
12. 10.1139/o82-07610.1139/o82-076 ↗
13. 10.3390/cells1002022010.3390/cells10020220 ↗
14. 10.1371/journal.pone.003456210.1371/journal.pone.0034562 ↗
15. 10.1021/ja508063s10.1021/ja508063s ↗
16. 10.1136/gutjnl-2011-30072110.1136/gutjnl-2011-300721 ↗
17. 10.1002/adhm.20210198410.1002/adhm.202101984 ↗
18. 10.1089/ars.2017.705810.1089/ars.2017.7058 ↗
19. 10.1038/nrd.2015.110.1038/nrd.2015.1 ↗
20. 10.1038/nrd443310.1038/nrd4433 ↗
21. 10.1016/j.ccr.2025.21674610.1016/j.ccr.2025.216746 ↗
22. 10.1002/adfm.20250738410.1002/adfm.202507384 ↗
23. 10.1161/CIRCRESAHA.118.31113410.1161/CIRCRESAHA.118.311134 ↗
24. 10.1038/s41467-019-14132-y10.1038/s41467-019-14132-y ↗
25. 10.1016/j.jconrel.2022.10.05510.1016/j.jconrel.2022.10.055 ↗
26. 10.1016/j.bioactmat.2022.03.04310.1016/j.bioactmat.2022.03.043 ↗
27. 10.1002/cbic.20240081710.1002/cbic.202400817 ↗
28. 10.1038/nm106110.1038/nm1061 ↗
29. 10.1021/jacs.8b0658410.1021/jacs.8b06584 ↗
30. 10.1021/jacsau.1c0012810.1021/jacsau.1c00128 ↗
31. 10.1038/s41467-024-48097-410.1038/s41467-024-48097-4 ↗
32. 10.1021/jacs.3c0323910.1021/jacs.3c03239 ↗
33. 10.1021/acs.orglett.7b0085810.1021/acs.orglett.7b00858 ↗
34. 10.1016/j.xcrm.2024.10143210.1016/j.xcrm.2024.101432 ↗
35. 10.1038/s41467-023-38601-710.1038/s41467-023-38601-7 ↗
36. 10.1021/jo00323a01910.1021/jo00323a019 ↗
37. 10.1093/nsr/nwaa03410.1093/nsr/nwaa034 ↗
38. 10.1002/med.2143310.1002/med.21433 ↗
39. 10.1126/sciadv.abc172510.1126/sciadv.abc1725 ↗
40. 10.1021/jacs.3c1191410.1021/jacs.3c11914 ↗
41. 10.1002/adma.20170234210.1002/adma.201702342 ↗